Overall, our data may help to optimize the selection of hematopoietic stem cell donors on the basis of immunogenetic KIR/HLA for ALL patients and identify the best NK cell candidates in immunotherapy for AML. The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.